The application of EGFR antagonists, and thus the suppression of Tregs function during this immune replenishment phase following CT-induced lymphopenia, may have the capacity to substantially improve the reactivation of anti-tumor immune responses and efficacy of CT (Figure 2). The gene discussed is EGFR; the disease is neoplasm.